At Curapath, we are committed to pushing the boundaries of polymer and lipid-based drug delivery. Today, we are excited to share that we have entered into a co-exclusive license agreement with Cristal Therapeutics to integrate their groundbreaking CliCr® bioconjugation platform into our technology and service portfolio.
CliCr® provides a powerful, scalable, and precise method for site-specific and stable conjugation of biomolecules, addressing one of the most persistent challenges in targeted drug delivery, reaching extrahepatic tissues with accuracy and efficiency.
Under this agreement, Curapath becomes the exclusive CDMO authorized to use the CliCr® platform for the targeted delivery of nucleic acids through polymer and lipid nanoparticles (LNPs). Both Curapath and Cristal Therapeutics will have rights to grant sublicenses within this rapidly evolving field.
What This Means for Curapath and Our Partners
Integrating the CliCr® technology directly strengthens our ability to design and manufacture next-generation targeted nanoparticles, enabling us to bring innovative solutions to our clients worldwide.
With CliCr®, we can further advance the development of LNPs engineered to target for instance pulmonary tissues , brain, T cells for in vivo CAR-T therapies and other extrahepatic sites previously difficult to reach.
This addition significantly expands our technological arsenal, allowing us to offer researchers, biotech innovators, and pharmaceutical partners a precise, robust, and scalable conjugation solution that accelerates the path toward safer and more effective targeted therapeutics.
Leadership Statements
Dr. Philippe Clavel, CEO of Curapath, shared:
“Active targeting remains one of the greatest challenges in advanced drug delivery. By integrating Cristal Therapeutics’ CliCr® platform, Curapath strengthens its leadership in next-generation delivery systems, including targeting LNPs to extrahepatic tissues. This alliance enables us to offer innovators a scalable, precise, and stable bioconjugation solution, accelerating the development of safer, more effective targeted therapies.”
Dr. Werner Cautreels, CEO of Cristal Therapeutics, added:
“We are very pleased to collaborate with Curapath, a strong and leading CDMO in the LNP field. This collaboration places CliCr® in an excellent position to become the standard in bioconjugation to nanoparticles for nucleic acid drug delivery. It is another example of the broad applicability of the CliCr® platform in therapeutic drug and diagnostic development.”
About Cristal Therapeutics and CliCr®
Cristal Therapeutics is a biotechnology company dedicated to the development of superior bioconjugates with improved therapeutic profiles for better treatment outcomes in patients. The company’s proprietary CliCr® copper-free click chemistry enables site-specific, rapid, and robust conjugation of a wide variety of biomolecules. Designed to operate under mild up to even extreme conditions, CliCr® offers superior performance for applications in antibody-drug conjugates (ADCs), targeted delivery systems, diagnostics, and more. The conjugation is known for its unmatched precision, compatibility and ease of manufacturing up to and including under GMP. CliCr® enhances therapeutic product quality by minimizing impurities and strengthening conjugate stability, resulting in extended circulation, higher efficacy, and improved patient safety.
To know more about cristal therapeutics visit: https://cristaltherapeutics.com/
